Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) | BMC Cancer | Full Text
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration | Journal of Clinical Oncology
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian | DDDT
ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair-deficient mCRPC: Updated Analyses
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial - The Lancet Respiratory Medicine
Rucaparib: the past, present, and future of a newly approved PARP inhi | OTT
Rucaparib: the past, present, and future of a newly approved PARP inhi | OTT
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. - Abstract - Europe PMC
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial - The Lancet Oncology
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ...
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Rucaparib – second PARP inhibitor hits the market for ovarian cancer | MDedge Hematology and Oncology
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events | International Journal of Gynecologic Cancer
Rucaparib | ≥99%(HPLC) | Selleck | PARP inhibitor
Blockbuster status competition intensifying for PARP inhibitors - Pharmaceutical Technology
Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer | ESMO
ASCO GU 2022: A Randomized, Double Blind, Biomarker Selected, Phase II Clinical Trial of Maintenance PARP Inhibition Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Rucaparib Arm
PARP Inhibitors: Where Are We in 2020 and What's Coming Next?
Enrolling Clinical Trials: Rucaparib for the Treatment of Pancreatic Cancer - Penn Medicine
Clovis Oncology Announces Availability of Rubraca®▽ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany | Business Wire
